Anticipated Product Launches And STAR Strategy Will Strengthen Future Position In Defense And Respiratory Protection

Published
17 Feb 25
Updated
02 Jul 25
AnalystConsensusTarget's Fair Value
UK£17.06
22.8% overvalued intrinsic discount
02 Jul
UK£20.95
Loading
1Y
64.2%
7D
-3.9%

Author's Valuation

UK£17.1

22.8% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 0.41%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 3.03%

AnalystConsensusTarget has increased revenue growth from 7.3% to 8.1% and increased future PE multiple from 24.5x to 27.2x.

Shared on09 Apr 25
Fair value Decreased 3.57%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 6.48%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 3.35%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 12%

AnalystConsensusTarget has decreased revenue growth from 8.1% to 6.9% and decreased future PE multiple from 28.8x to 24.8x.

Shared on13 Mar 25